Resolve Therapeutics, LLC

Sanabio, LLC

James Arthur Posada

Chris Gabel

Pamela Smolak

Sanjay Bhikhubhai Patel

Weihong Yu

The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Nucleic acid molecules encoding nuclease-albumin fusion proteins

The present disclosure provides soluble interferon receptors. The methods of the disclosure can be used to treat or prevent a condition associated with an abnormal immune response.

Polynucleotides heterodimers of soluble interferon receptors and uses thereof

The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Optimized binuclease fusions and methods

Therapeutic nuclease-albumin fusions and methods

Heterodimers of soluble interferon receptors and uses thereof

Growing community of inventors

St. Petersburg, FL, United States of America

James Arthur Posada